← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Janus-associated kinase (JAK) inhibitors
fedratinib
L01EJ02
Forms & Strengths
- immediate-release capsules: 100mg
- immediate-release capsules: 200mg
- immediate-release capsules: 300mg
- immediate-release capsules: 400mg
Adult Dosing
- starting dose: 400mg orally once daily
- reduce dose by 50% for severe hepatic impairment
- monitor for myelosuppression, hepatotoxicity and thrombosis
Pediatric Dosing
- safety and efficacy not established in pediatric patients
- not recommended for use in patients under 18 years
Indications
- treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis
- treatment of adult patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea
Mechanism of Action
- inhibits Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3)
- inhibits proliferation of hematopoietic cells
Contraindications
- hypersensitivity to fedratinib or its excipients
- baseline platelet count below 50,000/μL
Adverse Reactions
- anemia
- neutropenia
- thrombocytopenia
- elevated liver enzymes
- diarrhea
- nausea
- vomiting
- fatigue
Drug Interactions
- CYP3A4 strong inhibitors (e.g., ketoconazole) increase fedratinib levels
- CYP3A4 strong inducers (e.g., rifampin) decrease fedratinib levels
Curated Content: Needs Vetting Before Put to Clinical Use